ABSTRACT
La radiación ultravioleta ha sido usada durante décadas para el tratamiento de diversas enfermedades cutáneas. La radiación ultravioleta A1 (UVA-1) que tiene una longitud de onda entre los 340nm y 400 nm está disponible desde el año 1981, pero recién en las últimas dos décadas se ha estudiado, publicado y reportado su potencial uso terapéutico en la dermatología. Los primeros beneficios de su uso se reportaron en la dermatitis atópica donde se utilizaron dosis altas de UVA-1 para tratar las exacerbaciones severas de esta condición. Luego, nuevas indicaciones terapéuticas de su uso se fueron expandiendo a otras enfermedades cutáneas tales como: morfea, liquen escleroso, queratosis liquenoide, linfomacutáneo de células T y otras dermatopatías. La radiación UVA-1 al tener una longitud de onda más larga penetra a las capas más profundas de la dermis, lo que le permite una acción en la modificación de la respuesta inflamatoria, la respuesta inmunológica y los mecanismos de reparación cutánea.
Ultraviolet light radiation has been used for decades for the treatment of several cutaneous diseases. The ultraviolet radiation A1 (UVA-1) with a wave length between 340 nm-400 nm has been available since 1981, but only in the last two decades it has been studied and published for therapeutic use in dermatology. The first reported benefits of its use were reported in atopic dermatitis in which high doses of UVA-1were used to treat severe exacerbations of this condition. Thereafter, new therapeutic indications expanded its use for other cutaneous diseases like: morphea, lichen sclerosus, lichenoid keratosis, cutaneous T cell lymphoma and other skin conditions. The UVA-1 radiation has a long wavelength that make possible to reach the deep dermis and to modify the inflammatory response, immunological response and the cutaneous repair mechanisms.
Subject(s)
Humans , Skin Diseases/radiotherapy , Ultraviolet Therapy/methods , Apoptosis/radiation effects , Cytokines/radiation effects , Dermatitis, Atopic/radiotherapy , Scleroderma, Localized/radiotherapy , T-Lymphocytes/radiation effects , Lupus Erythematosus, Systemic/radiotherapy , Skin/radiation effects , Ultraviolet Therapy/adverse effectsABSTRACT
A radioterapia para o câncer da mama como para os de outros órgâos induz uma linfopenia significante. Em estudos anteriores de outros autores, há uma grande controvérsia sobre as proporçöes de diminuiçäo das populaçöes T e B. Quantificando os linfócitos T por rosetas E e os linfócitos B por imunofluorescência direta, observamos diminuiçäo semelhante das populaçöes. Pacientes com ou sem cirurgia prévia responderam do mesmo modo à radioterapia. Pacientes com linfopenia (<1500mm3) prévia à radioterapia sofrem reduçäo significativamente menor de ambas as populaçöes. Seis a oito semanas após a radioterapia já há recuperaçäo significante dos números de linfócitos T somente nas pacientes com mais de 60 anos.
Subject(s)
Humans , Female , Adult , Middle Aged , Breast Neoplasms/radiotherapy , B-Lymphocytes/radiation effects , T-Lymphocytes/radiation effects , Lymphopenia/etiology , Lymphocyte CountABSTRACT
We used the autoradiographic assay to assess human in vivo somatic cell gene mutation at the hypoxanthine guanine phosphoribosyl transferase (hgprt) locus in T-lymphocytes. Cells able to incorporate tritiated thymidine in vitro in 6-thioguanine containing shot-term cultures were enumerated in order to determine 6-thioguanine resistant (TGr) variant frequencies in cryopreserved lymphocytes from control indivuals and 3 persons suspected of 60Co exposure from an accident in Cd. Juárez, México. The data indicate that the lymphocyte TGr variant frequency assay may be potencially usefull for human population monitoring following accidental to ionizing radiation